GRAIL, Inc. Common Stock – Quartalsabschluss (NASDAQ:GRAL)

Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik

Vierteljährlich Jährlich

Market Capitalization 2.1359 B
Employee 910
Founded 2015
CEO N/A
Website www.grail.com
Headquarter Delaware, United States
FIGI BBG01N6CGW43
Industry Diagnostik und Untersuchungen

Gesamtumsatz

Jahresüberschuss

Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)

Gesamtverschuldung

Freier Cashflow

Zahlungsmittel und Zahlungsmitteläquivalente

2.14 B Marktkapitalisierung

Kurs-Gewinn-Verhältnis

-7.7

Preis-Umsatz-Verhältnis

21.37

GRAIL Inc

GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021. In June 2021 GRAIL launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023 EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024.